Aer is pleased to announce that our first patient has been dosed in our Phase 2a proof-of-concept clinical study of fexlamose (formerly "AER-01") in Chronic Obstructive Pulmonary Disease ("COPD"). The Phase 2a POC study (“AER-01-002”) is a randomized, double-blind, placebo controlled, parallel group study of fexlamose given once daily for 28 days to patients with COPD. Aer is utilizing a novel approach to identify and treat mucus plug-high COPD patients. Specifically, AER-01-002 will enroll 100 patients with moderate to severe COPD who are mucus plug-high. Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve lung function, lessen symptoms and improve quality of life. Fexlamose may also be developed for the treatment of other muco-obstructive lung diseases, including cystic fibrosis (CF) and non-CF bronchiectasis. https://lnkd.in/erhiftSV
关于我们
Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs. We are focused on treating respiratory diseases with significant unmet need, such as COPD, cystic fibrosis and asthma. Our technology was developed and spun out of Dr. John Fahy’s airway biology lab at University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarson’s glycochemistry lab at University College Dublin and Dr. Anne Marie Healy’s pharmaceutics lab at Trinity College Dublin. The efforts of this research consortium led to over $18M in NIH grant funding, resulting in the identification of our lead therapeutic candidate (AER-01), establishment of preliminary safety and efficacy profiles, and the production of clinical trial API.
- 网站
-
http://aertherapeutics.com
Aer Therapeutics, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- San Francisco，CA
- 类型
- 私人持股
- 创立
- 2014